1. Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.
- Author
-
Dobard, Charles, Makarova, Natalia, Nishiura, Kenji, Dinh, Chuong, Holder, Angela, Sterling, Mara, Lipscomb, Jonathan, Mitchell, James, Deyounks, Frank, Garber, David, Khalil, George, Spreen, William, Heneine, Walid, and García-Lerma, J Gerardo
- Subjects
- *
MACAQUES , *IMMUNODEFICIENCY , *HETEROSEXUAL men , *CONFIDENCE intervals , *URETHRA , *RNA virus infections , *PYRIDINE , *BIOLOGICAL models , *RESEARCH , *HIV integrase inhibitors , *PENIS , *ANIMAL experimentation , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *PREVENTIVE health services , *PRIMATES , *COMPARATIVE studies , *CHEMOPREVENTION , *INFECTIOUS disease transmission - Abstract
We used a novel penile simian-human immunodeficiency virus (SHIV) transmission model to investigate whether long-acting cabotegravir (CAB LA) prevents penile SHIV acquisition in macaques. Twenty-two macaques were exposed to SHIV via the foreskin and urethra once weekly for 12 weeks. Of these, 6 received human-equivalent doses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated. The efficacy of CAB LA was high (94.4%; 95% confidence interval, 58.2%-99.3%) and similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%). The high efficacy of CAB LA in the penile transmission model supports extending the clinical advancement of CAB LA preexposure prophylaxis to heterosexual men. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF